We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FNCH
76
DELISTED
Finch Therapeutics Group, Inc. Common Stock
FNCH
$4.11M 0.29%
10,524
-309
-3% -$132K
AVIR icon
77
CALL
Atea Pharmaceuticals
AVIR
$376M
$4.09M 0.29%
+116,600
New +$3.23M
RCOR
78
DELISTED
Renovacor, Inc.
RCOR
$4.01M 0.28%
442,902
+412,902
+1,376% +$4.03M
ALLK
79
PUT
DELISTED
Allakos
ALLK
$3.96M 0.28%
37,400
-300
-0.8% -$26.8K
FOLD
80
DELISTED
Amicus Therapeutics
FOLD
$3.95M 0.28%
414,174
+72,674
+21% +$743K
MGNX icon
81
MacroGenics
MGNX
$235M
$3.95M 0.28%
188,478
-271,124
-59% -$6.53M
FOLD
82
PUT
DELISTED
Amicus Therapeutics
FOLD
$3.85M 0.27%
+403,500
New +$4.13M
VSTM icon
83
Verastem
VSTM
$510M
$3.78M 0.27%
102,281
-13,919
-12% -$511K
OVID icon
84
Ovid Therapeutics
OVID
$414M
$3.71M 0.26%
1,105,082
-19,790
-2% -$72.2K
LYRA
85
DELISTED
LYRA THERAPEUTICS INC
LYRA
$3.69M 0.26%
8,069
-4,425
-35% -$1.67M
CRVS icon
86
Corvus Pharmaceuticals
CRVS
$1.12B
$3.67M 0.26%
757,545
+657,545
+658% +$1.95M
BCRX icon
87
CALL
BioCryst Pharmaceuticals
BCRX
$2.28B
$3.59M 0.25%
+250,000
New +$3.94M
AUTL
88
Autolus Therapeutics
AUTL
$397M
$3.57M 0.25%
544,819
-811,229
-60% -$5.12M
ISEE
89
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.52M 0.25%
+216,519
New +$2.36M
XENE icon
90
PUT
Xenon Pharmaceuticals
XENE
$6.06B
$3.52M 0.25%
+230,000
New +$4M
TRIL
91
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.48M 0.25%
198,400
-1,600
-0.8% -$18.7K
NXTC icon
92
NextCure
NXTC
$16.8M
$3.43M 0.24%
42,430
-643
-1% -$56.4K
IGMS
93
DELISTED
IGM Biosciences
IGMS
$3.39M 0.24%
+51,500
New +$3.94M
CLNN icon
94
Clene
CLNN
$64M
$3.34M 0.24%
24,466
+18,539
+313% +$3.16M
ALLK
95
DELISTED
Allakos
ALLK
$3.34M 0.24%
31,526
-174
-0.5% -$15.5K
TARA icon
96
Protara Therapeutics
TARA
$220M
$3.32M 0.23%
479,995
-104,809
-18% -$817K
TGTX icon
97
PUT
TG Therapeutics
TGTX
$7.96B
$3.28M 0.23%
98,600
-1,400
-1% -$43.3K
ISEE
98
CALL
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.25M 0.23%
+200,000
New +$2.18M
VINC
99
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$3.22M 0.23%
9,953
-11,384
-53% -$3.32M
PHAT icon
100
Phathom Pharmaceuticals
PHAT
$708M
$3.2M 0.23%
99,560
-440
-0.4% -$14.6K
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.